Skip to main content
Jay Lee, MD, Thoracic Surgery, Los Angeles, CA

JayMLeeMD

Thoracic Surgery Los Angeles, CA

Adult General Thoracic Surgery, Minimally Invasive Thoracic Surgery, Pediatric Thoracic Surgery, Thoracic Surgical Oncology

Thoracic Surgical Oncologist | Clinical Trials in Lung Cancer | Biotech

Dr. Lee is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Lee's full profile

Already have an account?

  • Office

    UCLA Medical Center
    10833 Le Conte Ave., 64-128 CHS
    Los Angeles, CA 90095
    Phone+1 310-794-7333
    Fax+1 310-794-7333

Summary

  • Jay M. Lee, M.D., is the Surgical Director of the Thoracic Oncology Program, and Associate Professor of Surgery (Tenure Track) at the David Geffen School of Medicine at UCLA. He previously served as Chief, Division of Thoracic Surgery and Chief, Section of Thoracic Surgery for over a decade.
    He received his medical degree from UCLA and training in General Surgery at Georgetown and Duke University Medical Centers. He completed a Thoracic Research Fellowship at Memorial Sloan Kettering Cancer Center and received Thoracic Surgery training at the Brigham and Women’s Hospital and Children’s Hospital Boston at Harvard Medical School.
    Dr. Lee has published extensively in the field of thoracic oncology and has a funded research laboratory. His scientific effort has focused on translational trials involving investigator-initiated immunotherapy in human lung cancer and modulation of the immunosuppressive tumor microenvironment.
    Dr. Lee is on the Steering Committee of several neoadjuvant or perioperative immunotherapy or targeted therapy trials in resectable non-small cell lung cancer (NSCLC) including LCMC3 (atezolizumab), CANOPY-N (canakinumab and/or pembrolizumab), NAUTIKA1 (alectinib, entrectinib, vemurafenib plus cobimetinib, pralsetinib, or stereotactic body radiation therapy plus atezolizumab),and GEOMETRY-N (capmatinib). Dr. Lee is also the Study Co-Chair for the Skyscraper-15 (phase 3 trial of adjuvant atezolzumab and tiragolumab). He is on the Scientific Advisory Committee for two Phase 3 Merck trials: Perioperative MK2870 (TROP2-ADC) and Adjvuant V940 (personalized mRNA cancer vaccine) with pembrolizumab. Dr. Lee is on the Executive Committee of the LCMC4/LEADER trial to define driver mutations in early stage NSCLC. Dr. Lee is an author on numerous peri-operative clinical trials including LCMC3 and IMPower 010 (adjuvant atezolizumab).
    Dr. Lee is Board-certified by the American Board of Surgery (ABS) and the American Board of Thoracic Surgery (ABTS).

Education & Training

  • Brigham and Women's Hospital/Children's Hospital
    Brigham and Women's Hospital/Children's HospitalFellowship, Thoracic Surgery, 2004 - 2006
  • Duke University Hospital
    Duke University HospitalResidency, Surgery, 2001 - 2004
  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterPost-Doctoral Fellowship, 1999 - 2001
  • MedStar Health/Georgetown-Washington Hospital
    MedStar Health/Georgetown-Washington HospitalResidency, Surgery, 1997 - 1999
  • David Geffen School of Medicine at UCLA
    David Geffen School of Medicine at UCLAClass of 1997

Certifications & Licensure

  • DC State Medical License
    DC State Medical License 1999 - Present
  • CA State Medical License
    CA State Medical License 2006 - 2026
  • NC State Medical License
    NC State Medical License 2001 - 2017
  • MA State Medical License
    MA State Medical License 2004 - 2016
  • VA State Medical License
    VA State Medical License 1998 - 2016
  • American Board of Surgery Surgery
  • American Board of Thoracic Surgery Thoracic and Cardiac Surgery

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly
  • Super Doctor SuperDoctors.com
  • Fellow (FACS) American College of Surgeons

Clinical Trials

Publications & Presentations

Lectures

  • Is Neoadjuvant or Adjuvant Immunotherapy in Our Future for Resected Non-Small Cell Lung Cancer? 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019

Professional Memberships